Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Myeloid sarcoma shows a high frequency of mutations activating the MAPK/ERK pathway and association with clonal hematopoiesis

D. Nann, TC. Schade, M. Overkamp, L. Mahmutovic, E. Bag, S. Forchhammer, J. Slotta-Huspenina, L. Boudova, K. Sotlar, L. Quintanilla-Martinez, I. Bonzheim, F. Fend

. 2025 ; 11 (5) : e70044. [pub] -

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25021696

Grantová podpora
Stemline Therapeutics GmbH

Myeloid sarcoma (MS) is a mass-forming extramedullary manifestation of myeloid blasts, either in relation to an underlying acute myeloid leukemia (AML), another myeloid neoplasm (MN) or as a de novo occurrence. Data on the genetic profile of MS are sparse. In this study, 41 MS of 34 patients, including 7 de novo cases and 24 patients with antecedent or synchronous MN, were analyzed with targeted next-generation sequencing (NGS), RNA-based fusion detection, and gene expression profiling (GEP). In 10 patients, a MS developed after stem cell transplantation for MN. Additionally, 21 available pre-transplant bone marrow biopsies (BMB) from 20 patients and 6 post-transplant BMB from 6 patients were investigated. The most frequently mutated gene was TET2 (41%), followed by NPM1 (38%) and NRAS (35%). Overall, 74% of the cases exhibited mutations affecting the MAPK/ERK pathway. AML-type fusions were detected in seven MS patients, who were younger than those without fusions (median 49 versus 67 years). Nine of 13 patients with a MN and available pre-transplant BMB showed additional mutations restricted to the MS, including an additional NRAS mutation in 3/5 cases with AML. Five of seven of patients with pre-transplant BMB without evidence of a MN revealed clonal hematopoiesis (CH), mostly shared TET2 mutations. Comparative GEP between BM and MS revealed upregulation of the MAPK/ERK pathway in MS and of gene sets relevant for interaction with the microenvironment. In conclusion, MS is characterized by a high incidence of MAPK/ERK pathway mutations and activation, frequent clonal evolution, and association with CH in elderly patients without recurrent AML-type fusions.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25021696
003      
CZ-PrNML
005      
20251023075802.0
007      
ta
008      
251014s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/2056-4538.70044 $2 doi
035    __
$a (PubMed)40906433
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Nann, Dominik $u Institute of Pathology and Neuropathology, University Hospital Tuebingen and Comprehensive Cancer Center South West, Tuebingen, Germany $1 https://orcid.org/000000023071793X
245    10
$a Myeloid sarcoma shows a high frequency of mutations activating the MAPK/ERK pathway and association with clonal hematopoiesis / $c D. Nann, TC. Schade, M. Overkamp, L. Mahmutovic, E. Bag, S. Forchhammer, J. Slotta-Huspenina, L. Boudova, K. Sotlar, L. Quintanilla-Martinez, I. Bonzheim, F. Fend
520    9_
$a Myeloid sarcoma (MS) is a mass-forming extramedullary manifestation of myeloid blasts, either in relation to an underlying acute myeloid leukemia (AML), another myeloid neoplasm (MN) or as a de novo occurrence. Data on the genetic profile of MS are sparse. In this study, 41 MS of 34 patients, including 7 de novo cases and 24 patients with antecedent or synchronous MN, were analyzed with targeted next-generation sequencing (NGS), RNA-based fusion detection, and gene expression profiling (GEP). In 10 patients, a MS developed after stem cell transplantation for MN. Additionally, 21 available pre-transplant bone marrow biopsies (BMB) from 20 patients and 6 post-transplant BMB from 6 patients were investigated. The most frequently mutated gene was TET2 (41%), followed by NPM1 (38%) and NRAS (35%). Overall, 74% of the cases exhibited mutations affecting the MAPK/ERK pathway. AML-type fusions were detected in seven MS patients, who were younger than those without fusions (median 49 versus 67 years). Nine of 13 patients with a MN and available pre-transplant BMB showed additional mutations restricted to the MS, including an additional NRAS mutation in 3/5 cases with AML. Five of seven of patients with pre-transplant BMB without evidence of a MN revealed clonal hematopoiesis (CH), mostly shared TET2 mutations. Comparative GEP between BM and MS revealed upregulation of the MAPK/ERK pathway in MS and of gene sets relevant for interaction with the microenvironment. In conclusion, MS is characterized by a high incidence of MAPK/ERK pathway mutations and activation, frequent clonal evolution, and association with CH in elderly patients without recurrent AML-type fusions.
650    12
$a myeloidní sarkom $x genetika $x patologie $7 D023981
650    _2
$a mutace $7 D009154
650    12
$a MAP kinasový signální systém $x genetika $7 D020935
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a kojenec $7 D007223
650    _2
$a předškolní dítě $7 D002675
650    _2
$a dítě $7 D002648
650    _2
$a mladiství $7 D000293
650    _2
$a mladý dospělý $7 D055815
650    _2
$a dospělí $7 D000328
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a klonální hematopoéza $x genetika $7 D000082182
650    _2
$a mutační analýza DNA $7 D004252
650    _2
$a DNA vazebné proteiny $x genetika $7 D004268
650    _2
$a dioxygenasy $x genetika $7 D049308
650    _2
$a nukleofosmin $x genetika $7 D000090243
650    _2
$a membránové proteiny $x genetika $7 D008565
650    _2
$a GTP-fosfohydrolasy $x genetika $7 D020558
650    _2
$a up regulace $7 D015854
655    _2
$a časopisecké články $7 D016428
700    1_
$a Schade, Tim-Colin $u Institute of Pathology and Neuropathology, University Hospital Tuebingen and Comprehensive Cancer Center South West, Tuebingen, Germany
700    1_
$a Overkamp, Mathis $u Institute of Pathology and Neuropathology, University Hospital Tuebingen and Comprehensive Cancer Center South West, Tuebingen, Germany
700    1_
$a Mahmutovic, Lejla $u Institute of Pathology and Neuropathology, University Hospital Tuebingen and Comprehensive Cancer Center South West, Tuebingen, Germany
700    1_
$a Bag, Eyyub $u Institute of Pathology and Neuropathology, University Hospital Tuebingen and Comprehensive Cancer Center South West, Tuebingen, Germany
700    1_
$a Forchhammer, Stephan $u Department of Dermatology, University Hospital Tübingen, Tübingen, Germany
700    1_
$a Slotta-Huspenina, Julia $u Institute of Pathology, Technical University of Munich, TUM School of Medicine, Klinikum rechts der Isar, Munich, Germany $u Institute of Pathology, Starnberg, Germany
700    1_
$a Boudova, Ludmila $u Biopticka Laboratory, Pilzen, Czech Republic
700    1_
$a Sotlar, Karl $u Institute of Pathology, Paracelsus Medical University, Salzburg, Austria
700    1_
$a Quintanilla-Martinez, Leticia $u Institute of Pathology and Neuropathology, University Hospital Tuebingen and Comprehensive Cancer Center South West, Tuebingen, Germany $1 https://orcid.org/0000000171565365 $7 xx0217537
700    1_
$a Bonzheim, Irina $u Institute of Pathology and Neuropathology, University Hospital Tuebingen and Comprehensive Cancer Center South West, Tuebingen, Germany $1 https://orcid.org/0000000277320788
700    1_
$a Fend, Falko $u Institute of Pathology and Neuropathology, University Hospital Tuebingen and Comprehensive Cancer Center South West, Tuebingen, Germany $1 https://orcid.org/000000025496293X
773    0_
$w MED00205747 $t The journal of pathology. Clinical research $x 2056-4538 $g Roč. 11, č. 5 (2025), s. e70044
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40906433 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20251014 $b ABA008
991    __
$a 20251023075807 $b ABA008
999    __
$a ok $b bmc $g 2416853 $s 1259859
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 11 $c 5 $d e70044 $e - $i 2056-4538 $m The journal of pathology. Clinical research $n J Pathol Clin Res $x MED00205747
GRA    __
$p Stemline Therapeutics GmbH
LZP    __
$a Pubmed-20251014

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace